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Background. Hepatitis C (HCV) treatment eﬃcacy among HIV patients is limited by poor treatment adherence and tolerance, but
few studies have examined the psychosocial determinants of treatment adherence and outcomes. Methods. Chart abstracted and
survey data were collected on 72 HIV patients who had received pegylated interferon and ribavirin to assess correlates of treatment
adherence, completion, and sustained virologic response (SVR). Results. Nearly half (46%) the sample had active psychiatric
problems and 13% had illicit drug use at treatment onset; 28% reported <100% treatment adherence, 38% did not complete
treatment (mostly due to virologic nonresponse), and intent to treat SVR rate was 49%. Having a psychiatric diagnosis was
associated with nonadherence, while better HCV adherence was associated with both treatment completion and SVR. Conclusions.
Good mental health may be an indicator of HCV treatment adherence readiness, which is in turn associated with treatment
completion and response, but further research is needed with new HCV treatments emerging.
1.Introduction
Over 30% of all HIV patients are estimated to be coinfected
with hepatitis C virus (HCV), and liver disease is now a
leading cause of death in this population [1–3]. Yet very
few(<10%)coinfectedpatientsactuallyreceiveHCVtherapy
[4–7], in part because of limited treatment eﬃcacy and
anticipated diﬃculty with treatment adherence. The advent
of pegylated-interferon (PEG-IFN) therapy in combination
with ribavirin (RBV) has led to dramatic improvements in
the eﬃcacy of HCV treatment, but response rates remain
limited, particularly among coinfected patients; sustained
virologic response (SVR), deﬁned as an undetectable HCV
viral load six months after the completion of treatment, is
roughly 20–45% among coinfected patients [8–13], and is
inversely associated with severity of immune suppression
[14].
The success of treatment is impeded by high rates of
premature treatment discontinuations and poor adherence
[15]. Rates of premature HCV treatment discontinuation
among coinfected patients is nearly double that of HCV
monoinfected patients, ranging from 25% in highly con-
trolled clinical trials [8] to 50% in community-based studies
[12, 13], with most of this dropout attributed to treatment
side eﬀects or early virologic nonresponse. HCV treatment
adherence research has largely focused on whether treatment
is completed and on amount of dose reductions in PEG-
IFN and RBV [16–20]. We are aware of only a few published
studies that have reported on patient adherence to HCV
therapy. Fumaz and colleagues found that over 98% of
HIV coinfected patients self-reported taking all doses of
PEG-IFN/RBV in the prior 2 weeks at weeks 12, 24, and
48 of treatment [21]. In a clinical trial sample of HCV
monoinfected subjects, Smith and colleagues found that2 AIDS Research and Treatment
at least 95% of subjects self-reported taking all doses of
PEG-IFN throughout the course of treatment, while the
proportion of patients who reported recent missed doses of
RBV increased from 10–25% over the course of treatment
[22]. Similarly, in a cross-sectional study of both HCV
monoinfected and HIV coinfected patients, Weiss et al.
found that only 8% reported missing a dose of PEG-IFN in
the past month, while 21% had missed a dose of RBV in the
past week [23].
Speciﬁc medical (e.g., anemia, neutropenia) [24, 25]
and psychiatric [26, 27] variables render patients vulnerable
to greater toxicities associated with PEG-IFN/RBV, which
may in turn predict treatment adherence and tolerance,
but correlates of HCV treatment adherence have seldom
been examined. In contrast, a large number of predictors
of HIV antiretroviral therapy (ART) adherence have been
identiﬁed, including variables related to patient demograph-
ics, psychosocial functioning, and disease characteristics
[28–30]. Similar variables may be associated with HCV
treatment adherence, but studies are needed to establish
these relationships.
In this report we document ﬁndings from a study of
HIV coinfected patients receiving HCV care at one of three
HIV clinics in Los Angeles. We assessed the frequency and
correlates of adherence, treatment completion, and SVR
among coinfected clients who had received PEG-IFN/RBV,
either currently or in the past.
2. Methods
2.1. Sample. The participating HIV clinics were located
at the Greater Los Angeles Veterans Administration (VA)
Medical Center, Harbor-UCLA Medical Center, and AIDS
Healthcare Foundation (AHF). During the 4-month study
enrollment period, the study coordinator at each site per-
formed a chart review of all patients attending the clinic for
a routine visit to identify those who were coinfected with
HCV and otherwise eligible. Patients were asked to provide
consent for a brief survey and abstraction of data from
their medical chart as they were waiting to be seen by their
provider.Onlypatientswhohadactuallyreceivedinterferon-
based HCV treatment were included in the analysis for this
paper. The study protocol was approved by the Institutional
Review Boards at RAND and the individual clinics.
2.2. Measures. We abstracted data that were closest and
prior to the date HCV treatment was started. In addition,
participants were asked to complete a brief questionnaire.
Demographic and background characteristics that were
assessed included age, gender, race/ethnicity, education,
employment, and relationship status.
HIVandHCVmedicalcharacteristicsthatwereabstracted
included CD4 cell count, HIV viral load, and whether or not
the patient was on HIV antiretroviral therapy at the start of
treatment. With regard to HCV and liver disease, measures
included HCV viral load and genotype.
Adherence to HCV and HIV medication regimens were
assessed with single visual analog scales. For each regimen
type, respondents were asked to rate their overall adherence
on a scale of 0% to 100% to show their “best guess about
how much of your prescribed HCV (HIV) medication you
took during the time you were (have been) on treatment.”
Respondents were only asked to rate their adherence to ART
if they were on ART at the time of the survey, whereas
the HCV adherence question was asked if the respondent
had ever been on HCV therapy (past or current). Due to
the highly skewed response distributions, and evidence that
self-reports overestimate adherence by 10–20% compared to
objective measures [30], these variables were dichotomized
using 100% in one category, and <100% as the other.
Clinic attendance was assessed by asking respondents
to report whether or not they had missed any scheduled
clinic appointments over the past 6 months. A dichotomous
variablewasthencreatedtorepresentnoneversusanymissed
appointments.
Psychosocial readiness for treatment adherence focused
on mental health and substance use. We extracted from chart
data whether the patient had a diagnosis of depression or any
other psychiatric disorder, and any documented problems
with alcohol or illicit drug use (marijuana, cocaine, heroin,
crystal methamphetamine or other) over the past 6 months,
at the start of HCV treatment. We also extracted whether the
patient was receiving any form of psychiatric treatment (e.g.,
psychotropic medication, counseling).
2.3. Data Analysis. Descriptive statistics were used to
examine the frequency distributions of variables. We used
bivariate statistics (independent 2-tailed t-tests, Chi Square
tests) to examine correlates of HCV treatment adherence,
treatment completion, and sustained virologic response in
separate analyses. Multivariate analysis was planned but not
performed due to so few variables being associated with the
outcome variables in the bivariate analysis; this is likely a
result of the small sample sizes and limited statistical power.
3. Results
We enrolled a sample of 173 patients in the study, of whom
127 (73%) had been oﬀered HCV treatment at some point,
and 72 (42%) had received PEG-IFN/RBV treatment (7
others were about to start treatment; 48 patients who had
been recommended treatment, opted to refuse or defer it).
Findings regarding factors associated with provider recom-
mendation of treatment [31], and patient acceptance and
initiationoftreatment[32],havebeenreportedelsewhere.In
this paper we report analyses on the data from the subgroup
of 72 treated patients.
Amongthe72patientswhohadreceivedHCVtreatment,
nearly all (94%) were male, mean age was 48.1 years (SD =
9.2), 51% were non-White (including 31% African Ameri-
can), 57% had received at least some college education, 33%
were employed, and 23% were currently in a relationship.
Regarding medical characteristics, the vast majority (91%)
were on ART, mean CD4 count at time of study entry was
534(SD=234),and79%hadanundetectableHIVviralload.
Most(71%)hadanHCVgenotypeof1or4,and43%hadanAIDS Research and Treatment 3
HCV viral load less than 800,000 copies. Nearly half (46%)
had documentation in their clinic chart of any psychiatric
problem at study entry, and 13% had documentation of any
illicit drug use in the 6 months prior to study entry.
3.1. Dose Adherence. Among the 72 treated patients, the
average length of time between treatment initiation and
study enrollment was 3.2 years (range: 64 days to 10.5 years).
All patients received once-a-week PEG-IFN injections and
twice daily oral RBV. The prescribed medication dosage was
notcollected.MeanadherencetothePEG-IFN/RBVregimen
over the entire period that the patient was on treatment
(past or current) was 93.8% (SD = 15.3; range: 10–100%);
72% (n = 49) reported 100% (“good”) adherence or not
missing any doses of either PEG-IFN or RBV, with the other
19 (28%) reporting less than 100% (“poor”) adherence; 4
participants did not respond to the adherence question, each
of whom did not successfully complete the full course of
treatment, which could suggest that they are more likely to
have been poor adherers. In bivariate analysis, compared to
good adherers, poor adherers were more likely to have any
activepsychiatricdiagnosisatthetimeoftreatmentinitiation
(67% versus 38%; P<. 05) (see Table 1); no other variables
were signiﬁcantly associated with HCV treatment adherence.
3.2. Treatment Completion. Of the 72 treated patients, 43
(60%) completed a full course of prescribed treatment (33
completed 48 weeks, ﬁve completed 24–32 weeks and ﬁve
c o m p l e t e d5 2t o7 2w e e k s ) ,3w e r es t i l lo nt r e a t m e n ta tt h e
time of the survey, and 26 (38% of the 69 with determined
treatment status) prematurely discontinued treatment. Of
the 26 who discontinued treatment, the primary reasons
included virologic nonresponse (n = 14) and adverse
events (n = 10); the other two patients discontinued due
to unspeciﬁed reasons. Excluding the patients who were
currently on treatment, we compared the 43 who success-
fully completed treatment with the 26 who discontinued
treatment. The only variable that was signiﬁcantly associated
with treatment completion in bivariate analysis was HCV
treatment adherence; 79% of those who completed the
full course of treatment reported good HCV treatment
adherence, compared to 55% of those who prematurely
discontinued treatment (P<. 05) (see Table 2).
3.3. Treatment Virologic Response. Among the 43 partic-
ipants who completed HCV treatment, 32 achieved an
SVR six months after treatment completion, while 7 had
detectable HCV RNA; the SVR status of the other 4 patients
was pending. When including the 26 patients who prema-
turely discontinued treatment, and excluding the patients
who were either still on treatment or whose SVR status was
pending, the intent to treat SVR rate for the sample was 49%
(32/65). Bivariate correlates of SVR included age and HCV
treatment adherence; those who achieved SVR were younger
(mean age = 45.9 versus 51.7; P<. 01) and more likely to
report good HCV treatment adherence (81% versus 59%;
P<. 05) (see Table 3).
4. Discussion
Slightly over 40% of our sample had received HCV treat-
ment, a much higher rate than treatment rates reported
in other studies of HIV coinfected patients [4–7], in part
becauseourratesreﬂectlifetimehistoryoftreatmentwhereas
manyotherstudiesreportanevaluationoftreatmenteligibil-
ity and initiation at a single time point. With the signiﬁcant
proportion of the sample having received HCV treatment,
we were able to examine the frequency and correlates of
treatment adherence, completion and virologic response.
Unlike adherence to ART, which has been subject to
extensive research over the past 15 years and has become
known as the Achilles Heal of ART [33], this study is
among the few that have examined dose-taking adherence
to PEG-IFN/RBV. The study ﬁndings suggest that most HIV
coinfected patients for whom treatment is recommended by
the physician and who actually initiate therapy are able to
adhere very well to HCV treatment, and good HCV dose-
taking adherence was signiﬁcantly associated with both HCV
treatment completion and SVR. Also, SVR rates were higher
than what has been reported in most industry clinical trials
[8–10] or other community samples [11–13]. Nonetheless,
a sizeable minority of patients reported missing medication
doses and prematurely discontinuing treatment.
Just under 30% of the sample reported problems with
missed doses of PEG-IFN/RBV, which is similar to what has
been found in other studies of HCV treatment adherence
[22, 23]. While our data revealed a signiﬁcant relationship
between HCV dose adherence and SVR, the level of dose
adherence needed to achieve SVR remains unknown. Hope-
fully, with the pending emergence of protease inhibitor-
based HCV treatments and associated vulnerability to drug
resistance, research addressing this question will receive
greater emphasis.
High rates of treatment discontinuation were observed,
but most stopped treatment early due to virologic non-
response. Fourteen percent of treated patients stopped
treatment prematurely due to treatment side eﬀects, which
is a lower rate than those reported in the literature, even
though our sample included diﬃcult-to-treat patients (e.g.,
current psychiatric or substance abuse problems) who are
typically excluded from clinical trials [8–10]. Our ﬁndings,
together with the improved ability to manage treatment side
eﬀects with aggressive use of pharmacologic agents (e.g.,
antidepressants, growth factors, and erythropoietin) [25, 27,
34], and higher SVR rates observed in recent studies [11], are
evidence of the viability of HCV treatment for a larger, more
generalized pool of coinfected patients.
While our data generally suggest good levels of adher-
ence, treatment completion, and even virologic response, it
is important to acknowledge that most of our sample had
ended their course of treatment prior to being surveyed for
this study, which limits our ability to draw inferences from
these data with regard to outcomes of HCV treatment. It is
quite possible that patients who have successful experiences
and outcomes from treatment are more likely to remain
engaged in care and thus be accessible for recruitment into
this study, whereas patients who discontinued treatment or4 AIDS Research and Treatment
Table 1: Patient characteristics and HCV treatment adherence.
Variable Good adherence (N = 49) Poor adherence (N = 19) P-value
Demographics
Male gender 94% 95% 0.89
African-American 27% 42% 0.21
Mean age (years) 48.5 47.1 0.59
Any college education 61% 47% 0.30
Employed 31% 42% 0.37
In a relationship 23% 26% 0.77
HIV Disease characteristics
Mean CD4 count (cells/mm3) 522 560 0.50
Mean log10 HIV RNA (copies/ml) 2.16 2.37 0.48
HIV RNA ≤400 83% 72% 0.35
HCV Disease characteristics
HCV genotype 1 or 4 69% 74% 0.73
Mean log10 HCV RNA (copies/ml) 6.04 6.22 0.46
HCV RNA <800,000 42% 44% 0.92
Psychosocial functioning
Depressed 35% 50% 0.26
Any psychiatric disorder∗ 38% 67% 0.04
Any drinking problem 14% 21% 0.50
Any illicit drug use 14% 11% 0.68
Any missed appointments (past 6 months) 31% 32% 0.94
Good ART adherence1 60% 54% 0.69
∗P<0.05.
1Good adherence is deﬁned as 100% adherence.
Table 2: Patient characteristics and HCV treatment completion.
Variable Treatment complete (N = 43) Treatment discontinued (N = 26) P-value
Demographics
Male gender 93% 96% 0.59
African American 30% 31% 0.96
Mean age (years) 47.2 50.9 0.12
Any college education 58% 58% 0.97
Employed 37% 31% 0.59
In a relationship 24% 19% 0.66
HIV Disease characteristics
Mean CD4 count (cells/mm3) 507 534 0.65
Mean log10 HIV RNA (copies/ml) 2.29 2.17 0.63
HIV RNA ≤400 79% 77% 0.81
HCV Disease characteristics
HCV genotype 1 or 4 65% 81% 0.17
Mean log10 HCV RNA (copies/ml) 6.08 6.24 0.39
HCV RNA <800,000 45% 38% 0.57
Psychosocial functioning
Depressive disorder 36% 50% 0.26
Any psychiatric disorder 40% 58% 0.15
Any drinking problem 12% 23% 0.21
Any illicit drug use 12% 15% 0.65
Any missed clinic appointments (past 6 months) 35% 23% 0.30
Good HCV treatment adherence
∗1 79% 55% 0.04
∗P< 0.05.
1Good adherence is deﬁned as 100% adherence.AIDS Research and Treatment 5
Table 3: Patient characteristics and sustained virologic response (SVR) to HCV treatment.
Variable SVR (N = 32) No SVR (N = 33) P-value
Demographics
Male gender 94% 97% 0.54
African-American 25% 30% 0.63
Mean age (years)∗ 45.9 51.7 0.01
Any college education 53% 58% 0.72
Employed 44% 27% 0.17
In a relationship 13% 27% 0.15
HIV Disease characteristics
Mean CD4 count (cells/mm) 486 522 0.51
Mean log10 HIV RNA (copies/ml) 2.43 2.09 0.20
HIV RNA ≤400 76% 81% 0.61
HCV Disease characteristics
HCV genotype 1 or 4 63% 79% 0.15
Mean log10 HCV RNA (copies/ml) 6.01 6.31 0.14
HCV RNA <800,000 46% 33% 0.31
Psychosocial functioning
Depressive disorder 41% 47% 0.67
Any psychiatric disorder 43% 56% 0.30
Any drinking problem 16% 18% 0.78
Any illicit drug use 16% 12% 0.68
Any missed clinic appointments 31% 27% 0.72
Good HCV treatment adherence
∗1 81% 59% 0.05
∗P = 0.05.
1Good adherence is deﬁned as 100% adherence.
were nonresponders may be more likely to drop out of care
and thus not to be represented in our sample.
Studies have been mixed with regard to the eﬀects
of depression and substance abuse on HCV treatment
adherence, completion, and response [26, 27, 35]. Our
data showed that having a current psychiatric disorder
was associated with lower adherence. Having a psychiatric
disorder was not signiﬁcantly associated with treatment
completion or response, but this was likely due to the
small sample size and low statistical power; those who
completed and responded to treatment had lower numerical
rates (by 10–15%) of active psychiatric disorders. Similarly,
alcohol and drug use was not associated with any of the
treatment outcomes, though rates of alcohol problems were
numerically less among those who adhered well to and
completed treatment. While these ﬁndings are preliminary
and further research is needed to more fully investigate these
relationships, the data suggestthat clinicians should consider
incorporating brief validated measures of mental health and
substance use as measures of treatment readiness. It is also
noteworthy that several patients in our sample who had
depression, other psychiatric disorders, and substance use
problems were among those who adhered well, completed
treatment, and achieved an SVR. These ﬁndings provide
further support for HCV treatment recommendations that
view such patients as worthy of being considered appropriate
treatment candidates and advocate for treatment decisions
to be made on an individual case basis [36], as opposed to
excluding them from treatment as a rule.
Aside from the limitations noted above, there are others
that need to be considered. We did not randomly select
patientstoparticipate,butwedidseektoenrollallcoinfected
patients who were consecutively attending the study sites
during the 4-month recruitment period. Our measure
of adherence is limited by our reliance on self-reports,
rather than objective measures; self-reported adherence
measures have been found to be signiﬁcantly associated
with HIV virologic outcomes [37], but we are not aware of
such a relationship being documented with HCV virologic
response. As previously alluded to, our overall measurement
was hampered by needing to rely on a combination of
retrospective data from clinic charts (the quality of which
is dependent on the completeness of documentation and
updatedassessmentsbytheclinicians)andcurrentlyassessed
survey data, rather than prospectively examining adherence
and its correlates from the point of treatment initiation.
Furthermore, our analysis did not include measures of
ﬁbrosis and other biomarkers that could contribute to our
understanding of which variables most inﬂuence treatment
outcomes.
In conclusion, the data from this study provide evi-
dence that HIV coinfected patients generally adhere well
to HCV treatment and many are able to achieve sustained
virologic response. Nevertheless, problems with missed6 AIDS Research and Treatment
doses, premature discontinuation, and nonresponse were
not uncommon, and HCV dose-taking adherence was
signiﬁcantly associated with both treatment completion
and sustained virologic response. With emerging protease
inhibitor HCV treatments likely to be more eﬀective, yet also
more complex and expensive, more susceptible to resistance
development, and possibly more toxic, how patients will
weigh the costs and beneﬁts of treatment, and the impact
on patient adherence and treatment outcomes is unclear.
Greater emphasis on research to examine adherence and
its determinants is needed to optimize HCV treatment
outcomes among HIV co-infected patients.
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